{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:18:29Z","timestamp":1776921509291,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jacc.2021.08.021","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T23:08:56Z","timestamp":1634080136000},"page":"1635-1654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19"],"prefix":"10.1016","volume":"78","author":[{"given":"Azita H.","family":"Talasaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Aghakouchakzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hessam","family":"Kakavand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Ariannejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakriti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh V.","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W.","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170123","article-title":"The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain","volume":"12","author":"Guo","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jacc.2021.08.021_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"10.1016\/j.jacc.2021.08.021_bib3","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"32","key":"10.1016\/j.jacc.2021.08.021_bib4","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-86747-5","article-title":"Low HDL and high triglycerides predict COVID-19 severity","volume":"11","author":"Masana","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2021.08.021_bib7","first-page":"11","article-title":"Targeting lipid rafts\u2014a potential therapy for COVID-19","author":"Sviridov","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jacc.2021.08.021_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000240","article-title":"MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV","volume":"4","author":"Sheahan","year":"2008","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.jacc.2021.08.021_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JVI.02576-13","article-title":"Inhibition of NF-\u03baB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival","volume":"88","author":"DeDiego","year":"2014","journal-title":"J\u00a0Virol"},{"issue":"9","key":"10.1016\/j.jacc.2021.08.021_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CPP41397","article-title":"Statins differ in their ability to block NF-kappaB activation in human blood monocytes","volume":"41","author":"Hilgendorff","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jacc.2021.08.021_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01120-15","article-title":"Statins may decrease the fatality rate of Middle East respiratory syndrome infection","volume":"6","author":"Yuan","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.jacc.2021.08.021_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2020.09.027","article-title":"Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION\/INSPIRATION-S studies","volume":"196","author":"Bikdeli","year":"2020","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04840-y","article-title":"Atorvastatin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Ghati","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jacc.2021.08.021_bib14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3389\/fphys.2020.624657","article-title":"Stimulating the resolution of inflammation through omega-3 polyunsaturated fatty acids in COVID-19: rationale for the COVID-Omega-F trial","volume":"11","author":"Arnardottir","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2021.08.021_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2021.01.018","article-title":"Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)","volume":"235","author":"Ambrosy","year":"2021","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1186\/s13063-020-04905-y","article-title":"Letter to the editor: study summary\u2014randomized control trial of omega-3 fatty acid supplementation for the treatment of COVID-19 related olfactory dysfunction","volume":"21","author":"Lerner","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jacc.2021.08.021_bib17","series-title":"Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia, Domain-Specific Appendix: Statin Therapy REMAP-CAP: REMAP-CAP","author":"REMAP-CAP","year":"2020"},{"key":"10.1016\/j.jacc.2021.08.021_bib18","author":"Kanagarantam"},{"key":"10.1016\/j.jacc.2021.08.021_bib19","series-title":"Effects of icosapent ethyl on inflammatory biomarkers in individuals with COVID-19\u2014VASCEPA COVID-19 CardioLink-9. Paper presented at: National Lipid Association Virtual Scientific Sessions","author":"Bhatt","year":"2020"},{"key":"10.1016\/j.jacc.2021.08.021_bib20","series-title":"Pharmacology of cholesterol and lipoprotein metabolism. In: Principles of Pharmacology: The Pathophysiologic Basics of Drug Therapy: Fourth Edition. Wolters Kluwer Health","author":"Krisko","year":"2016"},{"key":"10.1016\/j.jacc.2021.08.021_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/872370","article-title":"Mechanisms of action and efficacy of statins against influenza","volume":"2014","author":"Mehrbod","year":"2014","journal-title":"BioMed Res Int"},{"issue":"10","key":"10.1016\/j.jacc.2021.08.021_bib22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1084\/jem.20031132","article-title":"KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation","volume":"199","author":"SenBanerjee","year":"2004","journal-title":"J\u00a0Experiment Med"},{"issue":"4","key":"10.1016\/j.jacc.2021.08.021_bib23","first-page":"309","article-title":"Statins in the intensive care unit","volume":"12","author":"Merx","year":"2006","journal-title":"Curr Opin Crit Care"},{"issue":"15","key":"10.1016\/j.jacc.2021.08.021_bib24","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1111\/bph.13166","article-title":"Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-\u03b2 receptor III expression","volume":"172","author":"Sun","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2021.08.021_bib25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","article-title":"Simvastatin in the acute respiratory distress syndrome","volume":"371","author":"McAuley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jacc.2021.08.021_bib26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","article-title":"Rosuvastatin for sepsis-associated acute respiratory distress syndrome","volume":"370","author":"Truwit","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2021.08.021_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","article-title":"Statins: a viable candidate for host-directed therapy against infectious diseases","volume":"19","author":"Parihar","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.jacc.2021.08.021_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.jacc.2021.08.021_bib29","first-page":"3190","article-title":"Efficacy of statin therapy in patients with acute respiratory distress syndrome\/acute lung injury: a systematic review and meta-analysis","volume":"22","author":"Feng","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21553-1","article-title":"Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19","volume":"12","author":"Gupta","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jacc.2021.08.021_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0148607108324203","article-title":"The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data","volume":"32","author":"Pontes-Arruda","year":"2008","journal-title":"J\u00a0Parenter Enter Nutr"},{"key":"10.1016\/j.jacc.2021.08.021_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2020.07.005","article-title":"Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19","volume":"156","author":"Rogero","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jacc.2021.08.021_bib33","article-title":"The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models","author":"Davies","year":"2021","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.jacc.2021.08.021_bib34","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/nu12061616","article-title":"Nicotinamide riboside\u2014the current state of research and therapeutic uses","volume":"12","author":"Mehmel","year":"2020","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.jacc.2021.08.021_bib35","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1096\/fj.202001451","article-title":"COVID-19\u2014associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches","volume":"34","author":"Sorokin","year":"2020","journal-title":"FASEB J"},{"issue":"21","key":"10.1016\/j.jacc.2021.08.021_bib36","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jacc.2021.08.021_bib37","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.021_bib38","series-title":"INSPIRATION-S Investigators. Atorvastatin vs placebo in patients with COVID-19 admitted to the ICU: the INSPIRATION-S Trial","author":"Bikdeli","year":"2021"},{"issue":"17","key":"10.1016\/j.jacc.2021.08.021_bib39","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jacc.2020.07.069","article-title":"Coronavirus and cardiometabolic syndrome: JACC Focus Seminar","volume":"76","author":"Mechanick","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacc.2021.08.021_bib40","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.08.021_bib41","article-title":"Therapeutic anticoagulation in critically ill patients with Covid-19\u2014preliminary report","author":"Goligher","year":"2021","journal-title":"medRxiv"},{"issue":"15","key":"10.1016\/j.jacc.2021.08.021_bib42","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","article-title":"Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC State-of-the-Art Review","volume":"77","author":"Talasaz","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.021_bib43","first-page":"1","article-title":"Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective","author":"Lee","year":"2021","journal-title":"Arch Pharm Res"},{"issue":"8","key":"10.1016\/j.jacc.2021.08.021_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Wootton","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jacc.2021.08.021_bib45","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jacc.2021.08.021_bib46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jacc.2021.08.021_bib47","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jacc.2021.08.021_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"14","key":"10.1016\/j.jacc.2021.08.021_bib49","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jacc.2021.08.021_bib50","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14\u00a0days in hospitalized patients with COVID-19: a randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacc.2021.08.021_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.jacc.2021.08.021_bib53","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"24","key":"10.1016\/j.jacc.2021.08.021_bib54","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2021.08.021_bib55","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1161\/ATVBAHA.120.315551","article-title":"Beneficial effect of statins in COVID-19\u2013related outcomes\u2014brief report: a national population-based cohort study","volume":"41","author":"Lee","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.08.021_bib56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2015.11.001","article-title":"DHA-and EPA-derived resolvins, protectins, and maresins in airway inflammation","volume":"785","author":"Duvall","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2021.08.021_bib57","first-page":"107703","article-title":"Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?","author":"Darwesh","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2021.08.021_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.13630","article-title":"Physician variation in the de-adoption of ineffective statin and fibrate therapy","author":"Everhart","year":"2021","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jacc.2021.08.021_bib59","doi-asserted-by":"crossref","first-page":"110127","DOI":"10.1016\/j.mehy.2020.110127","article-title":"Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19","volume":"143","author":"Buschard","year":"2020","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.jacc.2021.08.021_bib60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/01902149409064387","article-title":"Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs","volume":"20","author":"Nagai","year":"1994","journal-title":"Experiment Lung Res"},{"issue":"24","key":"10.1016\/j.jacc.2021.08.021_bib61","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2021.08.021_bib62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacc.2021.08.021_bib63","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jacc.2021.08.021_bib64","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2021.08.021_bib65","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCOUTCOMES.111.964072","article-title":"Reducing the cardiovascular disease burden: justified means for getting to the end","volume":"5","author":"Bikdeli","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"22","key":"10.1016\/j.jacc.2021.08.021_bib66","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacc.2021.08.021_bib67","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/03007995.2020.1747416","article-title":"Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2021.08.021_bib68","first-page":"1","article-title":"Cardiovascular complications of COVID-19: pharmacotherapy perspective","author":"Talasaz","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10.1016\/j.jacc.2021.08.021_bib69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ane.12540","article-title":"High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis","volume":"134","author":"Pandit","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"27","key":"10.1016\/j.jacc.2021.08.021_bib71","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence\u2014focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2021.08.021_bib72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacc.2021.08.021_bib73","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2021.08.021_bib74","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/ehjcvp\/pvab008","article-title":"Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Lombardi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.jacc.2021.08.021_bib75","first-page":"7","article-title":"Nicotinamide: an update and review of safety & differences from niacin","volume":"25","author":"Huber","year":"2020","journal-title":"Skin Therapy Lett"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721059702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721059702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:45:37Z","timestamp":1760017537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721059702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":75,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0735109721059702"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.08.021","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.03.21256468","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}